Pharma companies surge on strong growth prospects

WuXi Biologics (Cayman) (2269) is expected to achieve accelerated year-on-year revenue growth this year, causing its stock price to surge more than five percent this morning, reaching a high of HK$17.8, with a turnover of HK$230 million.

Chief executive, Chen Zhisheng, said yesterday in a meeting that the group’s business and financial conditions remain strong, with 151 new projects added last year, bringing the total number of projects to 817.

BeiGene (6160) also surged over six percent this morning, driven by expectations of achieving positive operating income in 2025.